So much biological complexity
Our bodies contain approximately 20,000 genes encoded in our DNA. Each gene codes for a protein, yet we can produce over 100,000 different proteins from this genetic code. Moreover, our epigenetics allow us to replicate around 20 million different sections of this code, and when combined with glycans, this results in over 100 million different molecules—a truly staggering number.
Science is just beginning to understand the complex mechanisms that govern many of our bodily functions. In the last 20 years, the study of aging has advanced dramatically, with almost daily publications in the field.
Rather than using medication to target specific cells, it is becoming apparent that the treatment of aging—and indeed all diseases—will involve the gentle realignment of cellular metabolism. This will enable cells and their metabolic processes to function as designed, but at a more efficient, 'youthful' level.
Small chains of amino acids, known as peptides, appear to a primary mechanisms by which cells communicate enhancing the ‘youthfulness’ of the metabolism, our cells, tissues and organs. Supplementation with these peptides, thereby restoring their levels to more youthful levels, is expected to rejuvenate metabolic pathways and provide flow on positive effects down the metabolic pathway. I repeat: Unlike traditional medications that block enzymes and can cause side effects, peptides enhance pre-existing pathways to youthful levels, presenting a different safety paradigm.
The approval pathways for pharmaceutical products were designed for a different class of medications— patentable de novo molecules, foreign to our bodies, which work primarily by blocking enzymatic processes in our cells. Unfortunately, these enzymatic processes are not there by accident, and blocking invariably involve dthe risk of harmful side effects. Peptides like BPC-157 and Thymosin Beta 4, which have been used by tens of thousands of patients under clinical supervision in Australia alone, do not easily fit into this traditional pharmacology paradigm and thus may struggle to progress through the regulatory pathways of the FDA and TGA. The regulation seems to punish the use of these molecules IN SPITE of their safety. The regulators are perceived to be too close to the giants of the pharmaceutical industry, to receptive to their needs and indeed are often staffed by the same professionals.
In a truly diverse community with individuals having varied health goals and realities, these peptides represent a potential breakthrough in achieving optimal health and longevity, and regulatory agencies need to adopt measures to encourage a proactive safety culture amongst practitioners and patients rather than blanket bans.
Disclaimer: This information is for educational purposes only, it does not constitute medical advice. Please consult with your health care practitioner for personalised medical advice.